The impact of bupropion on psychomotor performance

Aviation Space and Environmental Medicine

Volumn 73, Issue 11, 2002, Pages 1094-1099

  Paul, Michel A ^a   Gray, Gary ^a   Kenny, Gord ^a   Lange, Marvin ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Aircrew; Antidepressants; Psychomotor performance; Side effects; Smoking cessation

Indexed keywords

AMFEBUTAMONE;

ADULT; AIRPLANE CREW; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EYE IRRITATION; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LOGIC; MALE; MENTAL DISEASE; MENTAL PERFORMANCE; NAUSEA; NERVOUSNESS; NORMAL HUMAN; PSYCHOMOTOR ACTIVITY; PSYCHOPHARMACOLOGY; RASH; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION; TASK PERFORMANCE; TREMOR; VERTIGO; WAKEFULNESS; XEROSTOMIA;

ADULT; AEROSPACE MEDICINE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MENTAL FATIGUE; MIDDLE AGED; MILITARY PERSONNEL; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; REACTION TIME; SLEEP INITIATION AND MAINTENANCE DISORDERS; TASK PERFORMANCE AND ANALYSIS;

EID: 0036829776     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ascher JA, Cole JO, Colin JN, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395-401.
2. Baddley AD. A 3 min reasoning test based on grammatical transformation. Psychonomic Science 1968; 10:341-2.
3. Cooper BR, Wang CM, Cox RF, et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Well-butrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 1994; 11:133-41.
4. Dale LC, Hurt RD, Hays JT. Drug therapy to aid in smoking cessation. Postgraduate Medicine 1998; 104(No. 6):75-84.
5. Ellison L, Morrison H, de Grogh M, Villeneuve P. Health consequences of smoking among Canadian smokers: An update. Chronic Dis Can 1999; 20:36-9.
6. Ferguson HB, Simeon JG. Evaluating drug effects on children's cognitive functioning. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8(4-6):683-6.
7. Ferry LH, Burchette R. Evaluation of buproprion versus placebo for treatment of nicotine dependence. In: New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Assoc., 1994:199-200.
8. Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Primary Care 1999; 26(3; September):653-69.
9. Harris DA, Pegram FV, Hartman BO. Performance and fatigue in experimental double-crew transport missions. Aviat Space Environ Med 1971; 24:980-6.
10. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of buproprion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174:173-8.
11. Heslegrave RJ, Angus RG. The effects of task duration and worksession location on performance degradation induced by sleep loss and sustained cognitive work. Behav Res Methods Inst Comp 1985; 17:592-603.
12. Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: A new approach. Psychophysiology 1973; 10:431-6.
13. Holm KJ, Spencer CM. Bupropion: A review of its use in the management of smoking cessation. Drugs 2000; 59(4):1007-24.
14. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281:72-6.
15. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release buproprion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-202.
16. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685-91.
17. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of buproprion sustained release and setraline in depressed outpatients. J Clin Psychiatry 1997; 58:532-7.
18. McGinnis J, Foege W. Actual causes of death in the United States. JAMA 1993; 270:2207-12.
19. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of buproprion, fluxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997; 61:476-87.
20. Paul MA, Gray G, Lange M. The impact of sertraline on psychomotor performance. Aviat Space Environ Med 2002; 73:964-70.
21. Paul MA, Pigeau RA, Weinberg H. CC130 pilot fatigue during re-supply missions to former Yugoslavia. Aviat Space Environ Med. 2001; 72:965-73.
22. Pipe AL, Reid R, Boucher K. Sustained-release bupropion as an aid to smoking cessation. Today's Therapeutic Trends 2000; 18:52-70.
23. Centers for Disease Control ad Prevention. Reducing the Health Consequences of Smoking. 25 Years of Progress: A Report of the Surgeon General. Rockville, MD: Centers for Disease Control, U.S. Department of Health and Human Services, 1989; (CDC) 89-8411.
24. Shiffman S, Johnston JA, Khayrallah M, et al. The effect of buproprion on nicotine craving and withdrawal. Psychopharmacology. 2000; 148:33-40.
25. Smoking cessation during previous year among adults United States. MMWR Morb Mortal Wkly Rep 1993; 42:504-7.
26. Weihs H, Houser T, Batey S, et al. Long-term treatment of depression with bupropion sustained-release. Presented at the 153rd Meeting of the American Psychiatric Association, May 13-18, 2000, Chicago, IL. Washington, DC: American Psychiatric Association, 2000.
27. Weinberg H, Jantzen KJ, Cheyne D, et al. Jetlag, gamma activity, and managing pilot fatigue. In: Posluns H, ed. Transport Canada Conference Proceedings TP 13375. Fatigue in Transportation Workshop: Multimodal Issues and Solutions, October 15-16, 1998. Ottawa: Transport Canada, 1998.
28. Wilkinson RT, Houghton D. Portable four-choice reaction time test with magnetic tape memory. Behav Res Methods Inst Comp 1975; 7:441-6.